Engflag

Exin

Quick links to important sections

Exin

There is no image.

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Exin

Property Description
Active Ingredient Cefixime
Forms Oral Tablets, Oral Suspension
Pharmacological Class Third-generation Cephalosporin Antibiotic
General Purpose To combat bacterial infections
Origin Synthetic

What Type of Medication is Exin (Cefixime)?

The medicinal product Exin is a prescription-only antibiotic whose active component is Cefixime, designed to combat susceptible bacterial infections. Cefixime is a Third-generation Cephalosporin, which belongs to the larger family of β-Lactam antibiotics. As a synthetic compound, Cefixime possesses broad-spectrum activity. This characteristic is a key differentiating factor, enabling its application against a wide variety of both Gram-positive and Gram-negative bacteria in diverse clinical scenarios.

Exin's Composition and Available Forms

Exin is a single-ingredient product composed solely of the active ingredient Cefixime. The medication is designed for oral administration and is available in two main drug forms: Oral Tablets and an Oral Suspension. The availability of the Oral Suspension form is a strategic feature, making it particularly suitable for Pediatrics and other patient groups who may require precise liquid dosing or have difficulty swallowing the tablet form.

General Purpose of this Broad-Spectrum Agent

The general purpose of Exin is to act as a potent bactericidal agent that actively kills the invading bacteria responsible for disease. Its core function involves targeting and destroying the structural integrity of the bacterial cells by interfering with their ability to build their protective cell wall. This targeted action provides the primary benefit of the medication: effectively clearing the underlying infectious process. For example, Cefixime is commonly utilized when a broad-spectrum approach is required to address infections where the precise bacterial agent is initially unknown, allowing prompt, effective intervention.

Regulatory References

  1. WHO Essential Medicines List

What side effects are possible with Exin?

Possible Side Effects and Safety Information

The safety profile of Exin (Cefixime) is documented through official regulatory classifications based on clinical trials and post-marketing surveillance. Adverse reactions are grouped by the affected system and the frequency of their occurrence.

Adverse Reaction Classification

Side effects predominantly involve the Gastrointestinal System, with diarrhea and loose stools classified as Common adverse reactions. Other common effects include nausea, abdominal pain, and headache. Uncommon effects listed in regulatory documents include rash and pruritus (itching).

Serious Adverse Reactions and Systemic Safety

Official labeling documents rare but clinically significant adverse reactions across various systems. Serious Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), have been reported. Severe Immune System Disorders, including anaphylactic shock, are also documented, alongside the risk of cross-hypersensitivity with other beta-Lactam antibiotics like penicillins.

Systemic safety notes include the possibility of severe gastrointestinal effects, such as Clostridium difficile-Associated Diarrhea (CDAD), which can occur during or up to two months after treatment. Adverse effects on major organs include acute renal failure, hepatitis, and disturbances in blood counts (e.g., hemolytic anemia).

Safety Considerations for Specific Populations

Safety constraints are noted for specific groups. Patients with renal impairment require particular consideration, as this condition may enhance the risk of central nervous system effects, such as seizures. The safety and effectiveness of Cefixime have not been established in infants less than six months of age. Additionally, the official label notes that the drug may cause a fall in prothrombin activity, requiring caution in patients with existing coagulation risks or those receiving anticoagulant therapy.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation on Exin (Cefixime) overdosage focuses on the risk of severe neurological manifestations. Overexposure is known to predispose individuals to the risk of encephalopathy, which may present clinically with signs such as confusion, impairment of consciousness, and abnormal movements. The most serious documented outcome is the possibility of convulsions or seizures associated with drug therapy.

A critical population-specific consideration noted in prescribing information is the significantly increased risk of these severe neurological events in patients with renal impairment. This risk is heightened when the body cannot effectively clear the medicine. General symptoms similar to common adverse reactions, such as diarrhea or vomiting, may also occur at high exposure levels.

Due to the potential for severe neurological outcomes, all regulatory guidance mandates that immediate medical assistance must be sought upon suspicion of overdosage. Individuals are required to seek emergency medical attention or contact a Poison Help line immediately, especially if the person has collapsed, had a seizure, or cannot be awakened.

Management is strictly symptomatic and supportive. Regulatory labels confirm that no specific antidote exists for Cefixime overdose. Furthermore, the official documentation states that Cefixime is not removed in significant quantities by hemodialysis or peritoneal dialysis, confirming that procedural clearance is generally ineffective.

Therapeutic Uses of Exin

What Exin Treats: Main Uses and Benefits

This medication is commonly used to treat infections caused by susceptible bacteria across several therapeutic domains. Its use is considered relevant in clinical settings that involve acute or unstable symptom patterns, contributing to easing the overall symptom load and supports short-term symptom management.

Exin is applied across domains where additional symptomatic support is needed for infections of the upper airways, throat, and ears, such as Otitis Media (middle ear), Tonsillitis, and Pharyngitis. It is commonly used to help with respiratory issues like acute exacerbations of chronic bronchitis and urogenital issues like uncomplicated urinary tract infections. For more serious systemic illness, it is relevant for easing symptoms related to Typhoid Fever and Shigellosis.

“The medication helps address symptom clusters that may become intense or disruptive, providing support that assists with maintaining functional stability during episodes of heightened discomfort.”

In situations where a bacterial cause is present, Exin helps manage symptoms related to physical discomfort and systemic imbalance, such as painful urination, fever, and difficulty swallowing. The medication supports patients during episodes of heightened discomfort, including pediatric patients (for whom the liquid suspension form is relevant) and adults with sensitivities to other antibiotic classes.

Quick Fact: Focus on Acute Pain and Systemic Discomfort

Exin is relevant for easing symptoms that create noticeable physiological strain, specifically targeting infectious pain, inflammation, and fever associated with acute bacterial processes.

Regulatory References

  1. NIH MedlinePlus overview of Cefixime

Eligibility and Restrictions for Use

Who Can and Cannot Use Exin?

This section summarizes the official population eligibility and exclusion criteria for Exin (Cefixime) as defined in regulatory documents. Eligibility is determined primarily by hypersensitivity status, age, and organ function.

Absolute Contraindications

The medicine is contraindicated for any patient with a known hypersensitivity or allergy to Cefixime itself, to any other cephalosporin antibiotic, or those with a history of a severe penicillin allergy [1.1, 4.4]. These groups must not use the medicine.

Age and Organ Function Eligibility

Population Group Regulatory Status
Infants (under 6 months) Safety and effectiveness have not been established [1.5].
Pediatric Patients (6 months and older) Approved for use under standard labeled conditions [4.4].
Renal Impairment (CrCl < 60 mL/min) Use is conditional; official dose adjustment is required [1.5].
Older Adults (Geriatric) No routine dose adjustment is specifically required [1.5].

Conditional and Restricted Use

Use during pregnancy should occur only if clearly needed [1.5]. For nursing mothers, regulatory labeling suggests that consideration should be given to temporarily discontinuing nursing [4.4]. Furthermore, the chewable tablet formulation is restricted for patients with Phenylketonuria (PKU) due to the presence of phenylalanine [1.1].

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Exin (Cefixime)

Interaction Scope

  • Medicinal product categories with documented interactions: Oral Anticoagulants, Uricosuric agents (Probenecid), Live Bacterial Vaccines, Anticonvulsants.
  • Specific interacting medicines (if explicitly listed): Warfarin, Probenecid, Carbamazepine.
  • Mechanistic basis of interactions (only if stated in label): Pharmacokinetic interaction via inhibition of renal tubular secretion (Probenecid); Pharmacodynamic interference with coagulation (Warfarin); Reciprocal elevation of plasma levels (Carbamazepine).
  • Timing-based interaction rules (if applicable): Administration of Live Typhoid Vaccine, Oral requires separation of at least three days after completion of Cefixime therapy to ensure adequate immune response.
  • Population-specific interaction notes (if applicable): Clearance is reduced in patients with Renal Impairment, potentially increasing systemic exposure.
  • Interaction-related restrictions: Co-administration with live bacterial vaccines is officially restricted due to antagonism of therapeutic effect.

Interaction Classifications (High-Level)

  • Interaction severity classification (as defined in official documents): Significant (e.g., interaction with oral anticoagulants).
  • Regulatory basis (EMA / FDA / etc.): Based on government prescribing information and monographs.
  • Interaction-context constraints (as defined in official documents): The interaction with food is defined as a change in the absorption rate (Tmax), not total amount. Diagnostic tests may show false-positive results for urine ketones and glucose using certain methods.

Resulting Interaction Structure

  • Official interaction statements:
    • Co-administration with oral anticoagulants has been associated with prolongation of Prothrombin Time (PT) and elevation of the International Normalized Ratio (INR).
    • Probenecid reduces Cefixime renal clearance, resulting in increased Cefixime plasma concentrations.
    • The antibiotic may interfere with the successful outcome of live bacterial vaccines, requiring a defined separation period.
    • Co-administration is reported to lead to elevated plasma levels of Carbamazepine.

Connection to the overall interaction profile (2–4 sentences): The regulatory profile of Cefixime is defined by interactions that affect drug exposure (Probenecid, Carbamazepine), potential pharmacodynamic interference with the coagulation cascade (Warfarin), and specific therapeutic restrictions concerning live bacterial vaccines. Furthermore, the official label documents constraints related to patients with renal impairment and the risk of diagnostic test interference with specific laboratory methods.

Mechanism of Action

How Exin Works

The mechanism of action for Exin (Cefixime) is focused entirely on disrupting the life cycle of susceptible bacteria through structural compromise. This action can be defined across two primary mechanistic domains that lead to cellular lysis.

Covalent Inhibition of Bacterial Cell Wall Synthesis

Exin's effect begins at the molecular level by acting as an irreversible covalent inhibitor of crucial bacterial enzymes known as Penicillin-Binding Proteins (PBPs). Specifically, the drug's core structure binds to and deactivates the transpeptidases required for the final, essential cross-linking of the peptidoglycan chains that form the rigid bacterial cell wall. The inhibition halts the structural assembly pathway, creating structural defects.

Induction of Cellular Lysis via Osmotic Failure

The resulting structural failure of the cell wall immediately exposes the bacterium to its own immense internal osmotic pressure. The weakened cell wall cannot withstand this pressure, initiating a rapid cellular cascade that culminates in cell lysis (rupture). This direct, bactericidal effect is the primary physiological consequence of the mechanism.

Dosage and Administration Information

Official Administration and Dosing Principles

Exin (Cefixime) is indicated for oral administration and is supplied as 400 mg and 200 mg oral tablets and an oral suspension for liquid dosing. To ensure the correct concentration, the oral suspension must be shaken well prior to use, and a calibrated measuring device should be utilized for accurate dosing. The tablets and capsules may be taken with or without food.

Standard Labeled Regimens

The standard adult daily dose is typically 400 mg. This quantity is administered either once daily or divided into two 200 mg doses taken every 12 hours. For pediatric patients aged six months and older, the dose is calculated based on body weight, at 8 mg/kg/day, also given once daily or in two divided doses. The established maximum dose for both adults and older children is 400 mg per day.

Procedural Constraints and Duration

Dosage adjustments are required for patients with impaired renal function. For adults with creatinine clearance (CrCl) ≤ 60 mL/min, the daily dose must be reduced to 200 mg or 300 mg to align with altered systemic clearance. The duration of the treatment course generally lasts 7 to 14 days, although a 10-day minimum course is specified for infections caused by Streptococcus pyogenes. If a dose is missed, it should be taken as soon as remembered, but two doses should not be taken at the same time.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Exin (Cefixime)

Evidence for Use in Acute and Uncomplicated Urinary Tract Infections (UTI)

Research exploring how Cefixime was studied for uncomplicated urinary tract infections (UTIs) has primarily involved Randomized Controlled Trials (RCTs) and comparative studies. Researchers monitored outcomes related to physical discomfort, such as painful urination and fever, alongside laboratory tests for bacteriological cure, which monitors changes in bacterial culture status of the bacteria causing the infection. Findings describe patterns observed in the studies related to measurements of short-term symptomatic and bacteriological change. The available evidence was assigned a high level of certainty in some reviews for short-term outcomes. However, research highlights that measured outcomes were associated with local resistance patterns; therefore, research is ongoing to monitor how well the medicine performs.

Evidence for Use in Otitis Media and Upper Airway Infections

Cefixime was studied for use in infections including Acute Otitis Media (middle ear infection), Pharyngitis, and Tonsillitis. The research exploring these conditions is largely based on Randomized Comparative Trials applied in studies examining patient-reported experiences of fever and pain, particularly among pediatric patients (children) with Otitis Media. Findings for Acute Otitis Media were generally consistent, research describing patterns related to patient condition in children when susceptible organisms were present. Research exploring the use in Pharyngitis and Tonsillitis also reported patterns of clinical outcome and monitors the culture status of the common bacterial cause. While this evidence was assigned a high level of certainty in some reviews, there is limited information for long-term outcomes regarding the sustained avoidance of recurrence.

What Is Still Uncertain About Exin: Gaps in the Research

Scientific reviews indicate several areas where research is ongoing or where the evidence base has limitations. There is limited information for long-term outcomes across nearly all indications, leaving the durability of the microbiological outcome not fully established. Comparative evidence is lacking or has shown mixed results for certain complicated infections, and certainty remains low. Additionally, the utility in research contexts is under constant review, as evidence quality varies across studies and is threatened by the continuous global emergence of antibiotic resistance.

Key Studies & References

  1. Cefixime Capsules FDA Full Prescribing Information and Indications

Frequently Asked Questions (FAQ)

Common questions about Exin (FAQ)

Q: Is Exin different from other medicines used for the same thing?

Regulatory documents classify Exin as a Third-generation Cephalosporin antibiotic. This places it within the larger beta-Lactam family of medicines. It is designed to fight susceptible bacterial infections by interfering with the structural assembly of the bacterial cell wall.

Q: How long does the effect of Exin usually last after taking it?

The drug is typically administered once a day or split into two doses taken every 12 hours. This dosing frequency is used to help maintain the required concentration of the active medicine in the body over the designated dosing interval.

Q: If I miss a dose of Exin, is that a big problem?

Official regulatory texts advise that a missed dose should be taken as soon as it is remembered. However, regulatory labeling indicates that two doses are not to be taken at the same time to compensate for a single missed dose.

Q: Can older adults safely use Exin?

Official product information indicates that for older adults, often referred to as geriatric patients, no routine dose adjustment is specifically required. This is based on the general regulatory review of the medicine in this population group.

Q: Is Exin safe to use during pregnancy, based on official information?

Regulatory labeling advises that the use of Exin during pregnancy should occur only if clearly needed. This is a standard caution, as animal studies used in drug development are not always predictive of how a medicine will affect human pregnancy.

Q: What kind of studies support the use of Exin?

Research supporting the use of Exin includes Randomized Controlled Trials (RCTs) and comparative studies. These studies monitor outcomes related to both bacteriological cure (clearing the bacteria) and patient-reported symptoms.

Q: Why does the official leaflet list so many possible side effects for Exin?

Official documents list adverse reactions observed during both initial clinical trials and through post-marketing surveillance once the drug is available to the public. This regulatory process involves documenting potential effects, including rare ones, and classifying them by frequency and the affected body system.

Q: What should I do if I feel dizzy after starting Exin?

Official adverse reaction reports have listed dizziness and headache as potential effects of the medicine. If an individual experiences dizziness or any side effect, they should seek information from a qualified healthcare professional.

Q: If I stop taking Exin suddenly, will anything happen?

Antibiotics are prescribed for a specific duration, generally 7 to 14 days. Prematurely discontinuing the course may potentially interfere with the therapeutic goal of clearing the bacterial infection, which is why completing the prescribed duration is often emphasized in the labeling.

Q: Can Exin be taken with a chronic condition like diabetes?

Official product information notes specific constraints for certain chronic conditions, such as the restriction of the chewable formulation for patients with Phenylketonuria (PKU). For other long-term conditions, consulting a healthcare provider provides the opportunity to assess whether the medication is appropriate.

Q: Do I need to change my activities while I am taking Exin?

Regulatory documents state that the medicine has no known direct influence on the ability to drive or use machinery. The potential for side effects, such as dizziness or headache, is noted in the label and may affect an individual’s ability to safely perform activities.

Q: Can Exin affect my ability to drive or operate machinery?

Official documents state that Exin has no known direct influence on the ability to drive or operate machinery. Individuals should consider the potential for side effects, such as dizziness, which could indirectly affect their performance.

Q: Does Exin cause weight gain or weight loss?

Changes in weight have been included in the official adverse reaction reports, although the frequency is rare or unspecified. Both unusual weight loss and rapid weight gain have been reported as potential effects of the medicine.

Q: How long does Exin stay in your system after you stop taking it?

Pharmacokinetic data from official sources indicates that the medicine is cleared from the body by the kidneys. Measurable concentration levels are typically reported for a period of 6 to 8 hours after a single dose.

Q: Does Exin interact with birth control pills?

Regulatory sources advise that Exin may decrease the effectiveness of hormonal contraceptives, which include birth control pills, patches, or rings. Individuals using these forms of contraception may benefit from discussing this potential interaction with a healthcare professional.

Q: Will Exin work for everyone who takes it?

Clinical studies show a range of outcomes. Efficacy depends on the susceptibility of the specific bacteria causing the infection and local resistance patterns. Official information reports a range of outcomes in clinical studies, noting that effectiveness is continually monitored due to the threat of antibiotic resistance.

Q: Is it normal to feel tired when starting Exin?

Tiredness and general weakness have been listed among the reported side effects of the medicine in official adverse reaction reports. If fatigue persists or causes concern, consulting a healthcare professional is appropriate.

Q: Can Exin cause changes in mood or anxiety?

Adverse reaction reports have included anxiety and general mental/mood changes such as confusion among the potential, though typically uncommon or rare, effects of the medicine.

Q: Are there any long-term safety concerns associated with Exin use?

Scientific reviews indicate that there is limited information available for long-term outcomes across nearly all indications studied. The current research base has limitations, meaning the durability of the effect and the long-term safety profile are not fully established by the available evidence.

Q: Is there a generic version of Exin available?

The active ingredient in Exin is Cefixime. This substance is an established generic name for an antibiotic in the Third-generation Cephalosporin class, which may indicate its availability as a generic product.

Q: Is the research on Exin focused on one specific population?

The research supporting Exin is diverse, covering distinct patient groups. Studies include those addressing Urinary Tract Infections (UTI) and those involving pediatric patients (children) with Otitis Media.

Q: Does Exin cause problems with sleep?

Official adverse reaction reports have noted effects such as drowsiness and increased night-time urination as potential side effects. If sleep is significantly disturbed, seeking information from a qualified healthcare provider is suggested.

Q: What is the typical age range for people prescribed Exin?

Official eligibility criteria indicate that the medicine is approved for use in a wide range of patients. This includes Pediatric Patients (six months and older) through to Older Adults (Geriatric).

Q: Is Exin a long-term or short-term treatment?

The duration of the treatment course is generally defined in official documents as lasting between 7 to 14 days. This short timeframe classifies the medicine as a short-term treatment for acute bacterial infections.

Q: Can I take Exin if I'm taking vitamins and minerals?

Official health guidance suggests that individuals provide their healthcare professional with a list of all nonprescription products, including vitamins and supplements, to allow for comprehensive monitoring.

Q: What should I watch out for in the first week of taking Exin?

Patients should monitor for common adverse reactions noted in official documents. These effects predominantly involve the gastrointestinal system and include loose stools, diarrhea, nausea, abdominal pain, and headache.

Q: Is Exin only available by prescription?

The medicinal product Exin is officially classified as a prescription-only antibiotic. This means it is only legally available through a valid prescription from a licensed healthcare professional.

Q: What is the general success rate of Exin in clinical trials?

Clinical research reports a range of outcomes that reflect the specific infection being treated and the patient population. For example, some studies for certain indications have reported a clinical success rate ranging between 73% to 94%.

How should Exin be stored and disposed of?

How to Store and Dispose of Exin

Storage of Exin (Cefixime) must strictly adhere to the conditions listed on the official regulatory labeling.

Storage Requirements

Exin tablets must be stored at Controlled Room Temperature, specifically 20 C to 25 C (68 F to 77 F), with permitted excursions to 15 C to 30 C. The medication must be kept in its original, tightly closed container and protected from moisture and direct light. It is mandated that Exin in any form must not be frozen.

Liquid Suspension Stability: The oral suspension must be discarded after 14 days of reconstitution, even if medicine remains unused.

Child Safety: All forms must be kept out of the reach of children and pets in a secure location.

Official Disposal Instructions

The preferred method for discarding unused or expired Exin is through a community drug take-back program. If this option is unavailable, the official procedure is to mix the medication with an undesirable substance (e.g., dirt or coffee grounds), place the mixture in a sealed container, and dispose of it in the household trash. Personal information must be scratched out from the original container before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Exin found in:

A-Z Index: